登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C8H15N7O2S3
化学文摘社编号:
分子量:
337.45
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
法莫替丁, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
SMILES string
N\C(N)=N\c1nc(CSCCC(=N)NS(N)(=O)=O)cs1
InChI key
XUFQPHANEAPEMJ-UHFFFAOYSA-N
biological source
synthetic
grade
pharmaceutical primary standard
agency
EP Reference Standard
API family
famotidine
form
solid
packaging
pkg of 110 mg
manufacturer/tradename
EDQM
storage condition
protect from light
application(s)
pharmaceutical (small molecule)
format
neat
shipped in
ambient
storage temp.
2-8°C
Gene Information
human ... HRH2(3274)
正在寻找类似产品? 访问 产品对比指南
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Biochem/physiol Actions
H2组胺受体拮抗剂；抗溃疡剂。
Application
This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia.
General description
Famotidine is a hydrophilic, cationic, histamine H2 receptor antagonist drug that effectively inhibits gastric acid secretion in humans.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Famotidine
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 29(1-2), 2609-2610 (2017)
Determination of famotidine in acid reduction tablets by HPTLC and videodensitometry of fluorescence quenched zones
Campbell AN and Sherma J
Journal of Liquid Chromatography and Related Technologies, 26(16), 2719-2727 (2003)
Determination of cimetidine, famotidine, and ranitidine hydrochloride in the presence of their sulfoxide derivatives in pure and dosage forms by high-performance thin-layer chromatography and scanning densitometry
Kelani KM, et al.
Journal of AOAC (Association of Official Analytical Chemists) International, 85(5), 1015-1020 (2002)
K Yoshimoto et al.
Clinical pharmacology and therapeutics, 55(6), 693-700 (1994-06-01)
Central nervous system toxicity of H2-receptor antagonists has rarely been confirmed by the respective elevated cerebrospinal fluid drug concentrations. We observed two hemodialyzed neurosurgical patients in whom mental deterioration and convulsions developed after intravenous famotidine therapy (10 and 40 mg/day).
R R Berardi et al.
Clinical pharmacy, 7(4), 271-284 (1988-04-01)
The pharmacodynamic, therapeutic, and toxicologic properties of famotidine are evaluated and compared with those of cimetidine and ranitidine. Famotidine, an H2-receptor antagonist with a thiazole nucleus, is approximately 7.5 times more potent than ranitidine and 20 times more potent than
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持